Ocugen Inc., a clinical stage biopharmaceutical company focused on therapies that address rare and underserved eye diseases, has completed its merger with Histogenics Corp. The combined company’s name will be “Ocugen Inc,” and the company is expected to begin trading on September 30, 2019, on The Nasdaq Capital Market under the ticker symbol “OCGN.”
The executive team of Ocugen has become the executive team of the combined company, led by Shankar Musunuri, Ph.D., M.B.A., as chairman, CEO and co-founder.
Dr. Musunuri said in a statement, “We believe shareholders will benefit from our broad pipeline, which includes OCU300, an orphan drug candidate for ocular graft versus host disease in Phase 3 clinical trials, our modifier gene therapy platform, and OCU400, our first gene therapy product with two distinct orphan drug designations for patients with inherited retinal diseases, and our retinal disease programs in wet age-related macular degeneration and retinitis pigmentosa.”
Also as previously announced, the combined company has a seven-person board, comprising: Dr. Musunuri (who serves as chairman of the board), Uday B. Kompella, Ph.D. (co-founder), Ramesh Kumar, Ph.D., Frank N. Leo, Manish Potti, Suha Taspolatoglu, M.D., and John Zhang, Ph.D.
